November 2022 - Page 12 of 23

WednesdayNov 16, 2022 1:54 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical…

WednesdayNov 16, 2022 1:18 pm

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Schedules Q3 2022 Earnings Call

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, has announced it will release financial numbers for its third quarter 2022 on Nov. 21, 2022, after market close. The company also plans to hold a conference call to discuss the financial results and corporate update report. That call will be held at 10 a.m. ET on Nov. 22, 2022. EverGen CEO Chase Edgelow will host the call. EverGen is an established independent renewable energy producer that acquires, develops, builds, owns and operates a portfolio of renewable natural gas, waste-to-energy and related infrastructure projects. To participate in the…

WednesdayNov 16, 2022 9:45 am

EverGen Infrastructure Corp.’s (TSX.V: EVGN) (OTCQX: EVGIF) FVB Expansion Project Breaks Ground to Provide Lift to Company’s Revenues and EBITDA Amid a Stronger Renewable Natural Gas Market

EverGen commenced construction at its Core RNG Expansion Project at Fraser Valley Biogas; project is advancing on schedule and on budget with expected completion in Q1 2023 Expansion is estimated to double FVB’s capacity to ~160,000 GJ of RNG per year; coupled with new long-term offtake agreement executed in current robust RNG market, it is expected to provide significant boost to company’s revenues and EBITDA As Canada’s early mover, EverGen seeks to consolidate assets across the country and leverage its expertise in designing and optimizing resilient facilities; with team that has seen more than a hundred RNG projects, company boasts…

WednesdayNov 16, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032 Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new…

TuesdayNov 15, 2022 3:16 pm

QualityStocksNewsBreaks – CubCrafters Inc. Secures SEC Qualification

CubCrafters, the leading designer and manufacturer of light-sport, experimental and Part 23 certified backcountry aircraft, today announced that it has been qualified by the Securities Exchange Commission (“SEC”) to make a $50 million public stock offering using the Regulation A+ exemption. This allows for the first outside investment ever in the history of this iconic company. Advised by Manhattan Street Capital, CubCrafters intends to raise up to $50 million in investment capital from its fans, customers, aviation enthusiasts, the investment community, and the general public. The offering price for first round investors is $5 per share, with a minimum of…

TuesdayNov 15, 2022 2:17 pm

QualityStocksNewsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) ‘Strikingly Different’ EV Crossover Tour Takes the Spotlight in Vegas, Heads to Texas

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has successfully completed the third stop of the Mullen FIVE Strikingly Different EV Crossover Tour in Las Vegas, Nevada. According to the announcement, Mullen continues onwards to Texas, with stops this week in Dallas and Houston. The Mullen FIVE EV vehicle on tour is equipped with a completely updated infotainment system that features PERSONA, Mullen’s proprietary Personal Vehicle Assistant (“PVA”), which utilizes facial recognition technology to provide every driver with a highly individualized experience. “This tour not only allows the public to see what Mullen has…

TuesdayNov 15, 2022 2:04 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has scheduled its Annual Meeting of Stockholders; the meeting is slated for Jan. 12, 2023. According to the announcement, any proposals to be considered for the meeting should be sent to the company’s principal executive offices in Las Vegas; all proposals must comply with the procedures for stockholder proposals in the company's bylaws and need to be received by the close of business on Nov. 25, 2022. The company will file the official Notice of Annual Meeting and Proxy Statement…

TuesdayNov 15, 2022 1:52 pm

QualityStocksNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in terms of safety and efficacy. While it is too early for formal conclusions to be made of these results, CycloSam generally performed how we expected it to perform, even given the lowest dosage in our dose-escalating study. This is all very encouraging,” said Douglas R.…

TuesdayNov 15, 2022 1:22 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug Drysdale. “In addition to our clinical work, we have been actively broadening our robust IP portfolio through securing strategic licensing agreements for preclinical psychedelic-based compounds that will support our ongoing drug development efforts. These recent…

TuesdayNov 15, 2022 11:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced its Q3 2022 financial report; the company also provided an update regarding its anticancer drug candidates. The report noted that significant progress has been made in CNSP’s key trial designed to study Berubicin’s efficacy in the treatment of recurrent glioblastoma multiforme (“GBM”); that progress includes multiple clinical trial sites being approved for enrollment along with 29 of 68 clinical sites in the United States and Europe already enrolling patients. The company anticipates…

Site Search

Company Search

Month: November 2022